ABBVIE INC. (ABBV) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 20...
ABBVIE INC.'s revenue increased 8.6% year over year, from $56.33B to $61.16B.
Net income decreased 1.2% over the same period, from $4.28B to $4.23B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt decreased by 8.5% to $61.44B.
Operating cash flow grew 1.2% to $19.03B.
ABBVIE INC. maintains a moderate net profit margin of 6.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $14.46B-0.0% | $1.56B | $10.25B | $3.83B | $5.45B | $143.42B | $71.08B | $6.03B |
| Q4 FY2024 | $15.10B+4.4% | $-22.0M | $10.71B | $-1.49B | $7.05B | $135.16B | $67.14B | $3.33B |
| Q1 FY2025 | $13.34B-11.6% | $1.29B | $9.34B | $3.73B | $1.64B | $136.16B | $66.12B | $1.42B |
| Q2 FY2025 | $15.42B+15.6% | $938.0M | $11.08B | $4.89B | $5.15B | $137.18B | $68.52B | $-183.0M |
| Q3 FY2025 | $15.78B+2.3% | $186.0M | $10.47B | $1.90B | $7.02B | $133.90B | $66.76B | $-2.64B |
| Q4 FY2025 | $16.62B+5.3% | $1.82B | $12.07B | $4.54B | $5.22B | $133.96B | $61.44B | $-3.27B |
| Q1 FY2026 | $15.00B-9.7% | $695.0M | $10.78B | $3.99B | $3.83B | $136.46B | $72.91B | $-6.61B |
| Q2 FY2026 | $16.99B+13.3% | $3.61B | $12.70B | $6.43B | $3.44B | $135.12B | $70.89B | $-5.89B |
Balance Sheet Summary (Q2 FY2026)
ABBVIE INC. (ABBV) Financial Statements & Revenue History
ABBVIE INC. (ABBV) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $285.95 with a market capitalization of $505. This page provides 42 historical financial statements for ABBVIE INC., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, ABBVIE INC. reported revenue of $61.2 billion, representing 8.6% year-over-year growth. The net profit margin of 6.9% indicates moderate profitability..
ABBV Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows ABBVIE INC.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ABBV is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ABBV's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently ABBVIE INC. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ABBV's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ABBV Financial Data
Investors use ABBVIE INC.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ABBV's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ABBV's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ABBV's financial health score, earnings, and pre-market pricing.
Financial data is sourced from ABBVIE INC.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ABBV trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.